Brokerages Set Hologic, Inc. (NASDAQ:HOLX) Target Price at $85.77

Hologic, Inc. (NASDAQ:HOLX) has been assigned a consensus recommendation of “Hold” from the seventeen brokerages that are covering the firm, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $85.77.

HOLX has been the topic of a number of research reports. Wolfe Research initiated coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Evercore ISI cut their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada dropped their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Finally, Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hedge Funds Weigh In On Hologic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic during the third quarter worth $25,000. General Partner Inc. acquired a new position in Hologic during the 4th quarter worth $26,000. Groupama Asset Managment increased its holdings in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 1.5 %

NASDAQ:HOLX opened at $63.53 on Monday. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52. Hologic has a twelve month low of $63.45 and a twelve month high of $84.67. The company has a market cap of $14.34 billion, a PE ratio of 20.04, a P/E/G ratio of 2.14 and a beta of 0.97. The company’s 50 day moving average is $71.53 and its two-hundred day moving average is $77.47.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts anticipate that Hologic will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.